Loading
A phase 3 trial of Elranatamab, Daratumumab, Lenalidomide in multiple myeloma, run by Pfizer, now recruiting.
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant is a phase 3 interventional study registered as NCT05623020 by Pfizer, with 1116 participants planned, started 2022-11-10 and due to reach its primary completion in 2030-10-18. Interventions recorded: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Elranatamab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen).
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.